HIV-1 genotypic drug resistance in patients with virological failure to single-tablet antiretroviral regimens in southern Taiwan

References

• Sterne JA, Hernán MA, Ledergerber B, et al. Long-term effectiveness of potent antiretroviral therapy in preventing AIDS and death: a prospective cohort study. Lancet. 2005;366(9483):378–384.
   PubMed Web of Science ®Google Scholar
• Bor J, Herbst AJ, Newell ML, Bärnighausen T. Increases in adult life expectancy in rural South Africa: valuing the scale-up of HIV treatment. Science. 2013;339(6122):961–965.
   PubMed Web of Science ®Google Scholar
• Jin Y, Liu Z, Wang X, et al. A systematic review of cohort studies of the quality of life in HIV/AIDS patients after antiretroviral therapy. Int J STD AIDS. 2014;25(11):771–777.
   PubMed Web of Science ®Google Scholar
• Kumarasamy N, Solomon S, Chaguturu SK, et al. The changing natural history of HIV disease: before and after the introduction of generic antiretroviral therapy in southern India. Clin Infect Dis. 2005;41(10):1525–1528.
   PubMed Web of Science ®Google Scholar
• Taniguchi T, Nurutdinova D, Grubb JR, et al. Transmitted drug-resistant HIV type 1 remains prevalent and impacts virologic outcomes despite genotype-guided antiretroviral therapy. AIDS Res Hum Retroviruses. 2012;28(3):259–264.
   PubMed Web of Science ®Google Scholar
• Rupérez M, Pou C, Maculuve S, et al. Determinants of virological failure and antiretroviral drug resistance in Mozambique. J Antimicrob Chemother. 2015;70(9):2639–2647.
   PubMed Web of Science ®Google Scholar
• Lai CC, Liu WC, Fang CT, et al. Transmitted drug resistance of HIV-1 strains among individuals attending voluntary counselling and testing in Taiwan. J Antimicrob Chemother. 2016;71(1):226–234.
   PubMed Web of Science ®Google Scholar
• Weng YW, Tsai HC, Lee SS, et al. Prevalence and associated factors for HIV-1 transmitted drug resistance in voluntary clients for counseling and testing in Southern Taiwan. J Microbiol Immunol Infect. 2016;49(4):487–493.
   PubMedGoogle Scholar
• Tsai HC, Chen IT, Wu KS, et al. High rate of HIV-1 drug resistance in treatment failure patients in Taiwan, 2009-2014. Infect Drug Resist. 2017;10:343–352.
   PubMed Web of Science ®Google Scholar
• Centers of Diseases Control Taiwan.: Statistics of HIV/AIDS; 2017. Available from: https://www.cdc.gov.tw/english/submenu.aspx?nowtreeid=F6F562FD95FD8DF9&treeid=00ED75D6C887BB27. Accessed January 27, 2018.
   Google Scholar
• Bangsberg DR, Ragland K, Monk A, Deeks SG. A single tablet regimen is associated with higher adherence and viral suppression than multiple tablet regimens in HIV+ homeless and marginally housed people. AIDS. 2010;24(18):2835–2840.
   PubMed Web of Science ®Google Scholar
• Airoldi M, Zaccarelli M, Bisi L, et al. One-pill once-a-day HAART: a simplification strategy that improves adherence and quality of life of HIV-infected subjects. Patient Prefer Adherence. 2010;4:115–125.
   PubMed Web of Science ®Google Scholar
• Blanco JL, Montaner JS, Marconi VC, et al. Lower prevalence of drug resistance mutations at first-line virological failure to first-line therapy with atripla vs. tenofovir + emtricitabine/lamivudine + efavirenz administered on a multiple tablet therapy. AIDS. 2014;28(17):2531–2539.
   PubMed Web of Science ®Google Scholar
• Cotte L, Ferry T, Pugliese P, et al. Effectiveness and tolerance of single tablet versus once daily multiple tablet regimens as first-line antiretroviral therapy - Results from a large french multicenter cohort study. PLoS One. 2017;12(2):e0170661.
   PubMed Web of Science ®Google Scholar
• Canducci F, Barda B, Ceresola E, et al. Evolution patterns of raltegravir-resistant mutations after integrase inhibitor interruption. Clin Microbiol Infect. 2011;17(6):928–934.
   PubMed Web of Science ®Google Scholar
• Canducci F, Ceresola ER, Boeri E, et al. Cross-resistance profile of the novel integrase inhibitor Dolutegravir (S/GSK1349572) using clonal viral variants selected in patients failing raltegravir. J Infect Dis. 2011;204(11):1811–1815.
   PubMed Web of Science ®Google Scholar
• Wensing AM, Calvez V, Günthard HF, et al. Update of the Drug Resistance Mutations in HIV-1. Top Antivir Med. 2017;2017(24):132–133.
   Google Scholar
• Gallien S, Flandre P, Nguyen N, et al. Safety and efficacy of coformulated efavirenz/emtricitabine/tenofovir single-tablet regimen in treatment-naive patients infected with HIV-1. J Med Virol. 2015;87(2):187–191.
   PubMed Web of Science ®Google Scholar
• Gagliardini R, Bandera A, Zaccarelli M, et al. 3-Year efficacy and durability of simplification to single tablet regimens: a comparison between co-formulated efavirenz/emtricitabine/tenofovir and rilpivirine/emtricitabine/tenofovir. Antivir Ther. 2018;23:139–148.
   PubMed Web of Science ®Google Scholar
• Armenia D, di Carlo D, Calcagno A, et al. Pre-existent NRTI and NNRTI resistance impacts on maintenance of virological suppression in HIV-1-infected patients who switch to a tenofovir/emtricitabine/rilpivirine single-tablet regimen. J Antimicrob Chemother. 2017;72(3):855–865.
   PubMed Web of Science ®Google Scholar
• Porter DP, Kulkarni R, Fralich T, Miller MD, White KL. Characterization of HIV-1 drug resistance development through week 48 in antiretroviral naive subjects on rilpivirine/emtricitabine/tenofovir DF or efavirenz/emtricitabine/tenofovir DF in the STaR study (GS-US-264-0110. J Acquir Immune Defic Syndr. 2014;65(3):318–326.
   PubMed Web of Science ®Google Scholar
• Palella FJ, Fisher M, Tebas P, et al. Simplification to rilpivirine/emtricitabine/tenofovir disoproxil fumarate from ritonavir-boosted protease inhibitor antiretroviral therapy in a randomized trial of HIV-1 RNA-suppressed participants. AIDS. 2014;28(3):335–344.
   PubMed Web of Science ®Google Scholar
• DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. Updated October 17, 2017.
   Google Scholar
• Durant J, Clevenbergh P, Halfon P, et al. Drug-resistance genotyping in HIV-1 therapy: the VIRADAPT randomised controlled trial. Lancet. 1999;353(9171):2195–2199.
   PubMed Web of Science ®Google Scholar
• Baxter JD, Mayers DL, Wentworth DN, et al. A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy. CPCRA 046 Study Team for the Terry Beirn Community Programs for Clinical Research on AIDS. AIDS. 2000;14(9):F83–F93.
   PubMed Web of Science ®Google Scholar
• Falloon J. Time to genotype for selection of antiretroviral regimens in previously treated patients? Lancet. 1999;353(9171):2173–2174.
   PubMed Web of Science ®Google Scholar